Ardea Biosciences Initiates Phase I/II Cancer Combination Therapy Trial
Posted on: Friday, 17 October 2008, 09:00 CDT
Ardea Biosciences, a developer of small-molecule therapeutics, has initiated a Phase I/II study of RDEA119, its lead mitogen-activated ERK kinase inhibitor for the treatment of cancer, in combination with Nexavar, which is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anticancer agents, including sorafenib.
This Phase I/II study in patients with advanced cancer will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of RDEA119 in combination with Nexavar.
Barry Quart, president and CEO of Ardea, said: "RDEA119 represents an exciting, new opportunity in cancer treatment. The synergistic activity that we have seen in preclinical studies of RDEA119 in combination with a broad range of anticancer agents suggests that RDEA119 has the potential to enhance the current standard-of-care across multiple cancer indications."
Source: Datamonitor
Related Articles
- The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde
- Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
- U.S. Food and Drug Administration (FDA) Approves PREZISTA(R) Once-Daily As Part of Combination Therapy for Treatment-Naive Adults With HIV-1
- NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
- Study Finds New Version of QIAGEN's HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer By More Than Half When Combined With Appropriate Treatment
- Data From ArQule's Phase 1 Trial With C-Met Inhibitor, ARQ 197, Demonstrate Safety and Expanded Anti-Cancer Activity
- NCCN Announces Important Updates to Cancer- and Treatment-Related Anemia Guidelines
- ZIOPHARM Presents ZIO-201/202/203 Preclinical Data at AACR; Anti-Cancer Activity in Leukemia, Pancreas, and Prostate Cancers
- Studies of Nipent(R) in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-Versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting
 |
 |
User Comments (0)
RSS Feeds